Martinus Capelle | Distinguished Scientist II
Janssen

Expert with over 20 years in CMC activities spanning pre-clinical, early & late stage clinical development, formulation, analytical development, fill/finish process and manufacturing of peptide, protein, antibody, vaccines, viral vectors, cell and gene therapy. Enthusiast for innovation,enabling drug delivery technologies and advanced characterization methods. Key contributor that lead to market authorisation of J&J Ebola (Zabdeno, Mvabea) and Covid-19 (Jcovden) vaccines.